NCT02598440 - A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis | Biotech Hunter

Enrollment

341

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

May 31, 2005

Study Completion Date

May 31, 2005

Conditions

Postmenopausal Osteoporosis

Interventions

DRUG

Alendronate

Participants wil receive once-weekly oral alendronate (70 mg tablet)

DRUG

Ibandronate

Participants wil receive once-monthly oral ibandronate (150 mg tablet)

Trial Locations (54)

14127

Orchard Park

16502

Erie

16506

Erie

16635

Duncansville

19114

Philadelphia

19148

Philadelphia

19610

Wyomissing

19713

Newark

21209

Baltimore

23235

Richmond

23602

Newport News

27609

Raleigh

29464

Mt. Pleasant

30033

Decatur

30904

Augusta

33024

Pembroke Pines

33176

Miami

33180

Aventura

33409

West Palm Beach

33614

Tampa

35801

Huntsville

37203

Nashville

46202

Indianapolis

46601

South Bend

50314

Des Moines

53705

Madison

60612

Chicago

63031

Florissant

63128

St Louis

67207

Wichita

75234

Dallas

77024

Houston

80202

Denver

85006

Phoenix

85282

Tempe

89502

Reno

91321

Santa Clarita

91786

Upland

92056

Oceanside

92084

Vista

92108

San Diego

92653

Laguna Woods

92691

Mission Viejo

97401

Eugene

98105

Seattle

98144

Seattle

92103-6204

San Diego

06416

Cromwell

06708

Waterbury

04401

Bangor

01610

Worcester

08540

Princeton

08753

Toms River

02886

Warwick

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY